RE:RE:RE:RE:RE:RE:RE:RE:my hope is they convertBiostock, what cashflow is coming short term. There are resin sales but they are spread over the year and will likely only approach $25M in 2019.The only other sources of cash are partnership deals and the sale of non core assets. The Lazard transactions actions will not be sealed until Sept/October. Also the Pg deal will not be consummated until potential partners are convinced the the new, complex control measures meet FDA requirements. This is not a given. Partnership deals on 4050 are unlikely to be completed until after the placebo controlled AS and Ipf studies are completed and produce positive results (2021). Pli runs out of money this month, April. Indeed, the only sources of cash are the ATM and Thomvest loans and equity raises with new investors. Have I missed something? Please let me know:-)